← Back to Clinical Trials
Recruiting Phase 4 NCT03088852

NCT03088852 Magnesium Deficiency In Patients Hospitalized in Internal Medicine Wards

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03088852
Status Recruiting
Phase Phase 4
Sponsor Frieda Wolf
Condition Hypomagnesemia
Study Type INTERVENTIONAL
Enrollment 330 participants
Start Date 2017-05-10
Primary Completion 2025-12

Trial Parameters

Condition Hypomagnesemia
Sponsor Frieda Wolf
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 330
Sex ALL
Min Age 18 Years
Max Age 90 Years
Start Date 2017-05-10
Completion 2025-12
Interventions
Magnesium Citrate 100 MG

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Hypomagnesemia is a common entity in the inpatient and outpatient setting. in previous retrospective study hypomagnesemic patients have higher mortality and longer hospitalization. whether hypomagnesemia is merely a marker of poor prognosis, or whether replacing it can improve outcomes is unclear. The current standard of care is to discharge these patients without workup or further treatment, even if patients had received intravenous therapy while hospitalized. The investigator wish to examine prospectively whether giving replacement therapy affects mortality, length of hospital stay and overall well-being. In order to replete intracellular levels and replete magnesium stores, magnesium should be given for several months.

Eligibility Criteria

Inclusion Criteria: * Any patient admitted over the age of 18, has hypomagnesemia (magnesium level ≤1.9 mg/dL) and is able to give consent. Exclusion Criteria: * A patient unable to give consent. * A patient admitted for an elective procedure. * A patient in critical condition or dying. * Patients with advanced kidney disease with eGFR\<15ml/min or on dialysis. * Patients with severe diarrhea, precluding use of magnesium citrate. * Patients already receiving magnesium supplements. * Patients with severe malnutrition or life-threatening hypomagnesemia (serum level \<1mg/dL), requiring intravenous and oral replacement of magnesium.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology